Detalhe da pesquisa
1.
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.
Haematologica
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572568
2.
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the ß2 and ß1 subunits of the proteasome complex.
Haematologica
; 108(6): 1628-1639, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36727403
3.
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
Oncologist
; 25(2): 112-118, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043788
4.
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
Clin Cancer Res
; 29(1): 279-288, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282272
5.
Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.
Biomark Res
; 11(1): 52, 2023 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37194045
6.
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.
Commun Biol
; 6(1): 1299, 2023 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38129580
7.
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
Commun Biol
; 4(1): 799, 2021 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172833